Abstract:Objectives: This study aims to evaluate the safety of a new inactivated poliomyelitis vaccine (Sabin strains) (sIPV) for large-scale use in primary and booster immunizations, whether simultaneously administered with other vaccines or not and to explore the persistence of all vaccines at approximately six months after vaccination. Method: A total of 3200 infants were recruited into this study, including 2000 infants aged 2-3 months randomly assigned (1:1) into the "sIPV basic" or the "sIPV+DTaP" group for primary immunization of sIPV. Another 1200 children aged 18 months old and above were randomly assigned (2:2:1:1) into the "sIPV booster," "sIPV+HepA-I," "sIPV+MMR", or "sIPV+HepA-L" group for booster immunization of sIPV. Adverse events within 30 days of each vaccination dose in all participants were self-reported by guardians using a WeChat mini-program. Approximately 200 blood samples were collected at 5-7 months after the final vaccination to test for antibodies against poliovirus and other viruses. Results: 3198 participants in total were included in the safety study, including 1999 infants aged 2-3 months old and 1199 children aged 18-26 months old. For primary immunization, the incidence of adverse reactions in the "sIPV basic" and the "sIPV+DTaP" group were 3.19 and 6.21% (P = 0.001), respectively. For booster immunization, the incidences of adverse reaction for the "sIPV booster" group were 2.25%, while the incidence for the "sIPV +others" group in total was 2.50% (P = 0.788). Most adverse reactions were mild. Fever was the most common symptom in all groups. No vaccine-related serious adverse events (SAEs) were observed in this study. The seropositivity rates of antibodies in the "sIPV basic" and the "sIPV+DTaP" group were 92.31 and 100% against type 1 poliovirus (P = 0.031); 96.15% and 98.57% against type 2 poliovirus (P = 0.575); 98.08% and 91.43% against type 3 poliovirus (P = 0.237), respectively. Regarding booster vaccination with sIPV, whether co-administered with other vaccines or not, the seropositivity rates of antibodies against the three types of polioviruses were all 100%. Seropositivity rates of antibodies against hepatitis A, measles, mumps, and rubella were all no <77%, except for pertussis, which was <30%. Conclusion: sIPV demonstrated good safety and immune persistence for primary and booster vaccinations, whether administered singly or simultaneously. Antibodies against hepatitis A, measles, mumps and rubella were not disrupted by the co-vaccination. However, the seropositivity rates and geometric mean concentrations (GMCs) of antibodies against pertussis indicate the necessity for a booster dose.

Firstly Detecting and Conducting of Circulating Type Ⅰ Vaccine-derived Poliovirus in China

Epidemiological survey and genetic characterization of type 3 vaccine-derived poliovirus isolated from a patient with four doses of inactivated polio vaccine in Henan Province, China

An Outbreak of Type Π Vaccine-Derived Poliovirus in Sichuan Province, China: Emergence and Circulation in an Under-Immunized Population

Acute Flaccid Myelitis in Children in Zhejiang Province, China.

Dynamic changes in polioviruses identified by environmental surveillance in Guangzhou, 2009–2021

Vaccine-derived Poliovirus Surveillance in China During 2001–2013: the Potential Challenge for Maintaining Polio Free Status

Thirty Years of Experience of Acute Flaccid Paralysis Surveillance for Polio - China, 1993-2022

Isolation and characterization of a Sabin 3/Sabin 1 recombinant vaccine-derived poliovirus from a child with severe combined immunodeficiency

Cases of Residual Paralysis in an Acute Flaccid Paralysis Surveillance System — China, 2001−2010

Vaccine-Associated Paralytic Poliomyelitis - 8 PLADs, China, October 2012-March 2014.

Analysis on Status of Acute Flaccid Paralysis Cases Surveillance System in China in 2011

Serological investigation on the prevalence of poliovirus in Guangdong province: A cross-sectional study

Cross-border Collaboration Between China and Myanmar for Emergency Response to Imported Vaccine Derived Poliovirus Case

A Survey on Porcine Circovirus Type 2 Infection and Phylogenetic Analysis of Its ORF2 Gene in Hangzhou, Zhejiang Province, China

Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China

Wide circulation of type 1 vaccine-derived poliovirus strains in clinical specimens from suspected cases of poliomyelitis, their contacts and in wastewater in Madagascar since late 2020

Detection of human enterovirus 71 and coxsackievirus A16 in children with hand, foot and mouth disease in China.

Genetic Characterization of Porcine Circovirus Type 2 (pcv2) from Pigs in High-Seroprevalence Areas in Southeastern China

Outbreak Response to Circulating Vaccine‐Derived Poliovirus in Three Northern Regions of Ghana, 2019

Analysis on Working Status to Retain the Situation of No-polio in Jiangxi Province,2003

Generation of porcine circovirus type 4 virus-like particles and their use to detect serum antibodies